{
  "id": 20625656,
  "title": "#CTAD26: Lilly’s dopamine drug mevidalen fails Phase 2 study in Alzheimer’s",
  "url": "https://urgent.news/2026/11/18/ctad26-lillys-dopamine-drug-mevidalen-fails-phase-2-study-in",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-18T16:22:48.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/ctad26-lillys-dopamine-drug-mevidalen-fails-phase-2-study-in-alzheimers/"
  },
  "original_language": "en",
  "account": null,
  "summary": "BOSTON — A little-known therapy Eli Lilly has quietly been testing in people with mild and moderate Alzheimer’s disease has failed in its Phase 2 study. The experimental drug, called mevidalen, was dropped ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}